Regeneron Pharmaceuticals, Inc.

777 articles with Regeneron Pharmaceuticals, Inc.

• 

  FDA Action Alert: Regeneron and Sanofi have a Busy Week, Plus Heron and Nabriva

  4/29/2019

  This week has a number of approvals expected by the U.S. Food and Drug Administration. Let’s take a look.
• 

  Calixar Inks Exclusive Licensing Deal With Regeneron

  4/29/2019

  Calixar is providing Regeneron exclusive rights to its technology and expertise. Regeneron plans to work on developing antibodies against an undisclosed target in several different therapeutic areas.

• FDA Approves Praluent® (alirocumab) to Prevent Heart Attack, Stroke and Unstable Angina Requiring Hospitalization

  4/27/2019

  Praluent is the first PCSK9 inhibitor that has shown a meaningful reduction in death from any cause

• CHMP Issues Positive Opinion for Libtayo® (cemiplimab) in Advanced Cutaneous Squamous Cell Carcinoma

  4/26/2019

  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the marketing authorization of Libtayo® (cemiplimab).

• 

  AbbVie Takes Top Spot in Best Place to Work Survey

  4/9/2019

  The study, which uses data gathered from Great Places to Work, points to the company’s openness from its leadership and the treatment of its employees as the primary reason it took the top spot.

• Regeneron to Report First Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on May 7, 2019

  4/8/2019

  Regeneron Pharmaceuticals, Inc. announced that it will report its first quarter 2019 financial and operating results on Tuesday, May 7, 2019, before the U.S. financial markets open.

• Regeneron and Alnylam Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases

  4/8/2019

  Companies to also jointly advance select number of preclinical disease programs with targets expressed in the liver and treatments for C5 complement-mediated diseases

• Alnylam and Regeneron Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases

  4/8/2019

  Companies to Also Jointly Advance Select Number of Preclinical Disease Programs with Targets Expressed in the Liver and Treatments for C5 Complement-Mediated Diseases

• 

  Regeneron and Alnylam Ink $1 Billion Eye and Central Nervous System R&D Deal

  4/8/2019

  Under the terms of the agreement, Regeneron is paying $400 million upfront to Alnylam and acquiring another $400 million in equity at a price per share of $90, or 4.44 million common shares.

• Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease

  3/15/2019

  Approval is based on ODYSSEY OUTCOMES trial of 18,924 patients who recently suffered an acute coronary syndrome such as a heart attack

• Teen Scientists Win $1.8 Million at Regeneron Science Talent Search 2019 with Innovative Ideas on Exoplanets, HIV and a Classic Math Problem

  3/13/2019

  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science & the Public announced that Ana Humphrey, 18, of Alexandria, Virginia, won the top award in the Regeneron Science Talent Search, the nation's oldest and most prestigious science and math competition for high school seniors.

• Regeneron and Sanofi to Present New Praluent® (alirocumab) Data at ACC.19

  3/13/2019

  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that four new sub-analyses from the Praluent® (alirocumab) ODYSSEY OUTCOMES cardiovascular (CV) outcomes trial will be presented at the American College of Cardiology's 68th Annual Scientific Session (ACC.19), held March 16-18, in New Orleans, LA.

• FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents - March 12, 2019

  3/12/2019

  Only therapy that targets the IL-4/IL-13 pathway, a key driver of the allergic or type 2 inflammation that underlies atopic dermatitis In a Phase 3 trial, Dupixent significantly reduced the extent and severity of disease and itching, and helped adolescents achieve clearer skin   [12-March-2019]   TARRYTOWN, N.Y. and CAMBRIDGE, Mass. , March 12, 2019 /PRNewswir

• 

  FDA Green-Lights Two Therapies, While Late-Stage Successes Set Stage for Potential Approvals

  3/12/2019

  The U.S. Food and Drug Administration has been busy approving new treatments for various diseases. Two days into the new week and the regulatory agency has green lit two therapeutics, while other companies are planning to file for potential approval.
• 

  Cowen Conference Spotlight: Biogen, Regeneron and Lilly Provide Insight

  3/12/2019

  With Cowen & Company’s 39th Annual Health Care Conference going on in Boston this week, a lot of stories in the biopharma industry are coming out. Here are a few highlights.

• FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents

  3/11/2019

  Only therapy that targets the IL-4/IL-13 pathway, a key driver of the allergic or type 2 inflammation that underlies atopic dermatitis

• 

  FDA Action Alert: Regeneron, Celgene and Aerie

  3/11/2019

  The next couple of weeks look to be busy for the FDA, with a string of target action dates scheduled. This week marks three scheduled approvals, two for extra indications for already-approved biologics, and the third for a combination treatment for glaucoma. Here’s a look.

• Regeneron Announces Upcoming Investor Conference Call - March 8, 2019

  3/8/2019

  Regeneron Pharmaceuticals, Inc. will webcast management participation

• CHMP Recommends Approval of Dupixent® (dupilumab) for Asthma Indication

  3/1/2019

  Regeneron Pharmaceuticals, Inc. and Sanofi announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion for Dupixent® in asthma.

• New Analyses to Be Presented at AAD for Dupixent® (dupilumab) and the Burden of Atopic Dermatitis

  3/1/2019

  Regeneron Pharmaceuticals, Inc. and Sanofi announced that the companies will present a diverse set of clinical and real-world data at the 2019 American Academy of Dermatology Annual Meeting from March 1 to 5 in Washington, D.C.